MedTrace Logo

ARNI Combined With SGLT2 Inhibitors on Functional Mitral Regurgitation Remodeling

NCT07379788 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 180

Last updated 2026-04-21

No results posted yet for this study

Summary

This study aimed to compare the effects of ARNI monotherapy versus combined ARNI and SGLT2 inhibitor therapy on Mitral Remodeling Index (MRIx) and Functional mitral regurgitation (FMR) remodeling in patients with heart failure with reduced ejection fraction (HFrEF).

Conditions

Interventions

DRUG

Sacubitril/Valsartan 49 MG-51 MG Oral Tablet [ENTRESTO]

Patients receiving Sacubitril/Valsartan 49 MG-51 MG Oral Tablet without concomitant SGLT2 inhibitor therapy.

DRUG

Empagliflozin10Mg Tab

Combination Therapy Group: Patients receiving Sacubitril/Valsartan 49 MG-51 MG Oral Tablet in combination with an SGLT2 inhibitor (empagliflozin 10 mg daily).

Sponsors & Collaborators

  • Tanta University

    collaborator OTHER

  • Madinah Cardiac Center in Madinah, KSA.

    collaborator UNKNOWN

  • Rehab Werida

    lead OTHER

Principal Investigators

  • Lamiaa Khedr, Ass Prof. · Madina Cardiac Center, KSA

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-25
Primary Completion
2026-02-28
Completion
2026-03-01

Countries

  • Saudi Arabia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07379788 on ClinicalTrials.gov